Pune, India, November 2018/MRFR Press Release/- Market Research Future published a half-cooked research report on the Global Aptamers Market.
The Global Aptamers Market is expected to register a growth of significant CAGR 20.2% during the forecast period (2018–2023).
Aptamers are oligonucleotides or peptide molecules that bind to a target lipid, nucleic acid molecules or proteins. They are generated rapidly and applied in the specific detection, inhibition, and characterization of proteins. Aptamers are multipurpose and cost-effective which offer complementary or alternative solutions to the antibodies. Growth in this market is credited to the improvements in aptamer development technologies, rising research and development investments for the development and manufacturing of recombinant products by major players and rising number of companies investing in this market are some of the key driving factors responsible for the growth of this market. Increasing use of aptamers in drug discovery and disease treatment may influence this market positively over forecast period. Other factors, such as the use of RNA aptamers have proven to be of high therapeutic and diagnostic value with recent FDA approval of the first aptamers drug and additional ones in the clinical pipelines eventually lead to the growth of aptamers market. Nevertheless, ethical issues in using aptamers, stringent regulations in use of aptamers and slow in reaching marketplace owing to regulatory hurdles may hinder the growth of this aptamers market over the estimated period.
The Global Aptamers Market has been segmented on the basis of type, application, technology and end users.
On the basis of type, the market has been classified as nucleic acid aptamers and peptide aptamers. The nucleic acid aptamers have been segmented into DNA-Based Aptamers, RNA-Based Aptamers. On the basis of application, the market has been classified as diagnostics, therapeutics development, research and development, other applications. On the basis of technology, the market has been classified as Selex, X-aptamer and MARAS technique. On the basis of end users, the market has been classified as academic and government research institutes, biotechnology and pharmaceutical companies, contract research organizations and other end users.
Access Report Details @ https://www.marketresearchfuture.com/reports/aptamers-market-6630
The Americas is projected to lead the aptamers market in the forecast period. Increasing healthcare awareness, advancement in technology, medical tourism are some other factors that boost the growth of the market.
The European market is expected to hold the second largest market share. The market is expected to witness growth owing to the rising patient population, changing lifestyle, and growing elderly population. This is expected to provide favorable backgrounds for the market to grow.
Asia-Pacific is projected to be the fastest growing region for the global aptamers in 2018. The market is expected to register positive growth owing to enlarged opportunities in diagnostics and development of pharmaceuticals which remain untapped in the aptamers market.
The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.
Some of the key players in the global aptamers market are Aptamer Sciences, Inc., Aptagen, LLC, Base Pair Biotechnologies, Inc., Ophthotech Corporation, Am Biotechnologies, LLC, Aptamer Solutions Ltd., Aptus Biotech S.L., Neoventures Biotechnology Inc., Somalogic, Inc., Trilink Biotechnologies, Inc., Vivonics, Inc., Noxxon Pharma, and others.